...
首页> 外文期刊>Heart rhythm: the official journal of the Heart Rhythm Society >Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead.
【24h】

Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead.

机译:阻抗监控失败,无法防止因召回的高压植入式心脏复律除颤器导线断裂而引起的不良临床事件。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The Medtronic Sprint Fidelis implantable cardioverter-defibrillator high-voltage lead is prone to fracture. The October 2007 safety advisory recommended lead impedance monitoring to aid in identifying lead fractures. OBJECTIVE: The aim of this single-center study was to examine the effectiveness of impedance monitoring for detecting Sprint Fidelis lead failures before they caused adverse clinical events such as inappropriate shocks. METHODS: Impedance and sensing information were acquired during routine clinic and CareLink follow-up and at the time of lead failure using the Patient Alert, sensing integrity counter, nonsustained episode, and electrogram features in Medtronic pulse generators. RESULTS: Between September 2004 and February 2008, 17 of 514 Sprint Fidelis leads (3.3%) followed up at our center failed between 11 and 35 months after implantation (mean 23.0 +/- 8.0 months). Fifteen of these failures (88%) were caused by pace-sense conductor fractures, and 2 (12%) were caused by high-voltage conductor defects. Twelve of 15 patients (80%) with pace-sense conductor fractures received inappropriate shocks; of these, 4 had no significant increase in lead impedance before they were shocked, 2 were shocked <3 hours after their lead impedances exceeded the 1,000 Omega audible alert threshold, and 2 patients did not hear the alarm. All pace-sense conductor failures whose sensing function could be evaluated (13 of 15) had oversensing based on stored data, and oversensing usually (11 of 13) preceded impedances changes. CONCLUSION: Impedance monitoring did not prevent inappropriate shocks in two-thirds of our patients. Thus, pace-sense conductor impedance monitoring as currently implemented does not reliably forewarn patients of a lead malfunction. Consequently, patients who have Sprint Fidelis leads remain at risk for adverse clinical events associated with pace-sense conductor fracture.
机译:背景:Medtronic Sprint Fidelis植入式心脏复律除颤器高压导线容易断裂。 2007年10月的安全公告建议监视导线阻抗,以帮助识别导线断裂。目的:这项单中心研究的目的是检查阻抗监测在Sprint Fidelis导线失效引起不良临床事件(例如不适当的电击)之前检测其有效性。方法:在常规诊所和CareLink随访期间以及在导联失败时,使用Medtronic脉冲发生器中的患者警报,感测完整性计数器,不持续发作和电描记图功能,获取阻抗和感测信息。结果:在2004年9月至2008年2月之间,我们中心的514条Sprint Fidelis牵头中有17条(占3.3%)在植入后11到35个月(平均23.0 +/- 8.0个月)内随访失败。这些故障中有十五个故障(占88%)是由于有节奏的导体断裂引起的,而有2个故障(占了12%)是由高压导体缺陷引起的。 15名患者中有12名(80%)出现了节奏感知型导体骨折,受到了不适当的电击。其中,有4名在电击前没有明显的导线阻抗增加,有2名在其导线阻抗超过1000Ω声音警报阈值后3小时内被电击,还有2名患者没有听到警报。可以评估其感应功能的所有步速感应器故障(15中的13)都基于存储的数据进行过感应,并且通常在阻抗变化之前进行过感应(13中的11)。结论:阻抗监测不能防止三分之二的患者受到不适当的电击。因此,当前实施的步速感知导体阻抗监测不能可靠地预知患者发生导线故障。因此,具有Sprint Fidelis导联的患者仍然面临与步速感知导体断裂相关的不良临床事件的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号